Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$1.57 -0.9%	$1.49	$1.01 ▼ $3.31	$443.94M	1.07	1.36 million shs	203,981 shs
ITOS iTeos Therapeutics	$10.16 +0.2%	$10.13	$4.80 ▼ $17.63	$448.95M	1.49	959,302 shs	2.54 million shs
MGNX MacroGenics	$1.70 -1.5%	$1.52	$0.99 ▼ $5.10	$107.14M	1.65	907,290 shs	393,473 shs
TECX Tectonic Therapeutic	$25.77 -3.0%	$22.22	$13.70 ▼ $61.07	$482.16M	3.27	260,913 shs	93,687 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	-1.25%	+8.22%	-7.06%	+8.97%	-41.91%
ITOS iTeos Therapeutics	0.00%	-0.78%	+0.20%	+1.00%	-41.65%
MGNX MacroGenics	-4.97%	+15.44%	+2.99%	+22.86%	-49.85%
TECX Tectonic Therapeutic	+3.39%	+10.30%	+16.80%	+18.57%	+40.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERAS Erasca	2.167 of 5 stars	3.4	1.0	0.0	2.0	2.5	0.6
ITOS iTeos Therapeutics	2.7647 of 5 stars	3.1	3.0	0.0	2.2	3.3	0.6
MGNX MacroGenics	4.3717 of 5 stars	3.3	3.0	4.4	2.8	4.2	0.0
TECX Tectonic Therapeutic	2.6099 of 5 stars	3.6	0.0	0.0	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	2.86	Moderate Buy	$4.29	173.85% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.50	52.63% Upside
MGNX MacroGenics	2.57	Moderate Buy	$3.60	112.39% Upside
TECX Tectonic Therapeutic	3.17	Buy	$80.33	211.73% Upside

Current Analyst Ratings Breakdown

Latest MGNX, ERAS, TECX, and ITOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ERAS Erasca	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00 ➝ $2.00
8/15/2025	MGNX MacroGenics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $5.00
8/7/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$12.00 ➝ $11.00
7/21/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/21/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00 ➝ $10.50
7/21/2025	TECX Tectonic Therapeutic	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
6/11/2025	TECX Tectonic Therapeutic	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$1.31 per share	N/A
ITOS iTeos Therapeutics	$35M	12.83	N/A	N/A	$11.17 per share	0.91
MGNX MacroGenics	$149.96M	0.71	N/A	N/A	$0.74 per share	2.29
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$15.16 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$161.65M	-$0.45	N/A	N/A	N/A	N/A	-31.19%	-26.34%	11/11/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$4.67	N/A	N/A	N/A	N/A	-33.26%	-28.16%	11/11/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.57	N/A	N/A	N/A	-21.99%	-40.24%	-14.62%	11/4/2025 (Estimated)
TECX Tectonic Therapeutic	-$57.98M	-$4.04	N/A	N/A	N/A	N/A	-30.13%	-28.33%	11/6/2025 (Estimated)

Latest MGNX, ERAS, TECX, and ITOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MGNX MacroGenics	-$0.59	-$0.57	+$0.02	-$0.57	$28.06 million	$22.24 million
8/12/2025	Q2 2025	ERAS Erasca	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
8/7/2025	Q2 2025	TECX Tectonic Therapeutic	-$0.98	-$1.07	-$0.09	-$1.07	N/A	N/A
8/6/2025	Q2 2025	ITOS iTeos Therapeutics	-$1.12	-$1.51	-$0.39	-$1.81	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	11.03	11.04
ITOS iTeos Therapeutics	N/A	7.53	7.53
MGNX MacroGenics	N/A	5.26	5.02
TECX Tectonic Therapeutic	N/A	25.60	25.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
ITOS iTeos Therapeutics	97.16%
MGNX MacroGenics	96.89%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	14.40%
ITOS iTeos Therapeutics	14.20%
MGNX MacroGenics	13.00%
TECX Tectonic Therapeutic	38.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	120	283.67 million	242.82 million	Optionable
ITOS iTeos Therapeutics	90	44.21 million	37.93 million	Optionable
MGNX MacroGenics	430	63.21 million	54.99 million	Optionable
TECX Tectonic Therapeutic	120	18.71 million	11.60 million	N/A

MGNX, ERAS, TECX, and ITOS Headlines

Recent News About These Companies

Tectonic Therapeutic to Participate in September Investor Conferences

August 28 at 9:00 AM | globenewswire.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from Brokerages

August 24, 2025 | marketbeat.com

15,369 Shares in Tectonic Therapeutic, Inc. $TECX Acquired by Cliffwater LLC

August 20, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Has $614,000 Stock Position in Tectonic Therapeutic, Inc. $TECX

August 20, 2025 | marketbeat.com

40,000 Shares in Tectonic Therapeutic, Inc. (NASDAQ:TECX) Bought by Knott David M Jr

August 12, 2025 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

August 11, 2025 | marketbeat.com

Tectonic Therapeutic Reports Q2 Financial Results

August 9, 2025 | theglobeandmail.com

Tectonic (TECX) Q2 R&D Soars 142%

August 7, 2025 | fool.com

Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

August 7, 2025 | manilatimes.netM

Tectonic Therapeutic (TECX) to Release Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Makes New $234,000 Investment in Tectonic Therapeutic, Inc. (NASDAQ:TECX)

August 1, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Rating of "Buy" from Analysts

July 28, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - Nasdaq

July 1, 2025 | nasdaq.com

Tectonic Therapeutic joins Russell 3000 index

June 30, 2025 | msn.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution

June 30, 2025 | quiverquant.comQ

Tectonic Therapeutic Joins Russell 3000® Index

June 30, 2025 | globenewswire.com

Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating

June 25, 2025 | msn.com

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

June 15, 2025 | finance.yahoo.com

Tectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock News

June 10, 2025 | gurufocus.com

LifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform Recommendation

June 7, 2025 | msn.com

Tectonic Therapeutic Holds 2025 Annual Stockholders Meeting

June 6, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX, ERAS, TECX, and ITOS Company Descriptions

Erasca NASDAQ:ERAS

$1.56 -0.02 (-0.95%)

Closing price 03:59 PM Eastern

Extended Trading

$1.56 0.00 (0.00%)

As of 04:03 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

iTeos Therapeutics NASDAQ:ITOS

$10.15 +0.03 (+0.25%)

Closing price 03:59 PM Eastern

Extended Trading

$10.18 +0.03 (+0.29%)

As of 04:05 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

MacroGenics NASDAQ:MGNX

$1.70 -0.03 (-1.45%)

Closing price 03:59 PM Eastern

Extended Trading

$1.70 +0.01 (+0.59%)

As of 04:04 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Tectonic Therapeutic NASDAQ:TECX

$25.77 -0.79 (-2.97%)

Closing price 03:59 PM Eastern

Extended Trading

$25.68 -0.09 (-0.33%)

As of 04:04 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time